Study medicine INCB000928 for fibrodysplasia ossificans progressiva
Part of Bones, joints & muscles clinical trials.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed clinical diagnosis of FOP.
- Your age fits one of these groups: 12+ years, or 6 to under 12 years, or 2 to under 12 years (with additional safety review for younger kids).
- You can and are willing to avoid pregnancy (if you can become pregnant) or fathering a child during the study period, using the study’s rules for contraception.
- You can complete low-dose whole-body CT scan imaging (not including the head) without needing a breathing tube (intubation).
- You are not pregnant and not breastfeeding.
- You do not have CAJIS score 24 or higher, and your FOP severity does not make the study too risky or not possible for you.
- You do not currently have an active infection needing prescription antiviral/antifungal/antibiotic treatment, and you are not living with HIV, hepatitis B (HBV), or hepatitis C (HCV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
This trial tests a new drug called garetosmab in children and teens with fibrodysplasia ossificans progressiva (FOP), a rare condition where muscle and soft tissue turn into bone. The goal is to see if garetosmab can help prevent or slow down these abnormal bone growths.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
This study tests a new medicine called OPF-110 to see if it is safe and tolerable in healthy adults. It will help determine if further testing in patients is possible.
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
Hear when a new Fibrodysplasia Ossificans Progressiva (FOP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.